Ardelyx's Adjusted Trial Design May Expedite NDA Filing For Lead Candidate
This article was originally published in The Pink Sheet Daily
The first-in-class NHE3 inhibitor tenapanor is in Phase III for IBS-C, as well as in Phase II for hyperphosphatemia in end-stage renal disease patients. Agreement with FDA may accelerate filing for the latter indication.
Register for our free email digests: